HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
EYE ON CHINA
Eisai's Aricept approved for additional indication of severe Alzheimer's disease in China
Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China.

Eisai Co., Ltd. announced that Aricept (donepezil hydrochloride) has been approved for the additional indication of severe Alzheimer's disease in China. Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China.

The approval of the additional indication was based on the results of a Phase III clinical study (Study 3391) in China. Study 339 was a multi-center, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of Aricept 10 mg per day in 313 Chinese patients with severe Alzheimer's disease. In this study, Aricept demonstrated a statistically significant improvement in total Severe Impairment Battery scores after 24 weeks compared to placebo, which was the primary endpoint of the study. In the study, the four most commonly observed adverse events in the Aricept arm were bradycardia, anorexia, QT interval prolongation, and dizziness.

In China, it has been estimated that approximately 6 million people suffer from Alzheimer's disease. Furthermore, with the progressive aging of the population, the number of patients with dementia is expected to greatly increase in the future.

With the approval of this indication covering severe Alzheimer's disease, Eisai strives to further contribute to increasing the quality of life of patients with Alzheimer's disease in China, and as the originator of Aricept, continues to make comprehensive contributions in dementia such as improving treatment and care, increasing public awareness of the disease and discovering new treatment methods.

Click here for the complete issue.

NEWS CRUNCH  
news Not Science Fiction anymore — the emergence of AI and Robotics in Healthcare
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy